Mind Medicine (MindMed), Inc. (NASDAQ:MNMD) Q3 2022 Earnings Conference Call November 10, 2022 8:30 AM ET
Company Participants
Robert Barrow - CEO & Director
Schond Greenway - CFO
Daniel Karlin - Chief Medical Officer
Conference Call Participants
Charles Duncan - Cantor Fitzgerald
Elemer Piros - ROTH Capital Partners
Patrick Trucchio - H.C. Wainwright & Co.
Sepehr Manochehry - Eight Capital
Operator
Good day, and welcome to the Mind Medicine Third Quarter 2022 Financial Results and Corporate Update Conference Call. [Operator Instructions]. As a reminder, this conference call is being recorded. It is now my pleasure to introduce your host, Robert Barrow, Chief Executive Officer and Director at Mind Medicine. Mr. Barrow, you may begin your conference.
Robert Barrow
Thank you, operator, and good morning, everyone. Welcome to MindMed's Third Quarter 2022 Financial Results and Corporate Update Conference Call. Prior to market open today, we issued a press release with a summary of our results for the third quarter of 2022. The press release reporting our financial results is available in the Investors and Media section of MindMed's website and our quarterly report on Form 10-Q for the quarter ended September 30, 2022, is planned to be filed today with the Securities and Exchange Commission.
Joining me today is Schond Greenway, our Chief Financial Officer; Dr. Dan Karlin, our Chief Medical Officer; and Dr. Miriam Wernli, our Executive President.
During the course of today's call, I will provide an overview and update on our business. Then Schond will review financial results for the quarter ended September 30, 2022, followed by Q&A. Before we begin, let me remind you that during this conference call, we will be making forward-looking statements. Company's actual results may differ materially from those expressed in or indicated by such forward-looking statements. For a description of risks, please refer to our recent filings with the Securities and Exchange Commission.
During the course of the third quarter, we continue to make significant progress across our business. Getting with MM-120 or LSD. In the third quarter, we dosed the first patient in our Phase IIb dose optimization study of MM-120 in the treatment of generalized anxiety disorder. Study enrollment has continued to progress according to plan, and we remain on target for a top line readout in late 2023.
In September, results from the LSD ASSIST study, which is a Phase II placebo-controlled investigator-initiated clinical trial of LSD and the treatment of anxiety disorders was, conducted by our collaborators at University Hospital, was published in the peer review Scientific Journal Biological Psychiatry. Top line results in 46 patients with clinically significant anxiety demonstrated the significant rapid, durable and beneficial effects of LSD and its potential to mitigate symptoms of anxiety and depression.